Form 4: Dexcom Director Bridgette P. Heller Sells 1,000 Shares Under 10b5-1 Plan

Dexcom director Bridgette P. Heller sold 1,000 shares of common stock at $76.87 per share on December 16, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Bridgette P. Heller, a director at Dexcom Inc., sold 1,000 shares of common stock on December 16, 2024.
• The sale was executed at a price of $76.87 per share.
• This transaction was conducted under a pre-established 10b5-1 trading plan adopted on February 25, 2024.
• Following the transaction, Ms. Heller beneficially owns 23,349 shares of Dexcom stock, which includes 2,618 unvested restricted stock units.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction under a pre-arranged plan, indicating a neutral sentiment.

Industry Context

This is a routine transaction for a company director and is not unusual. The use of a 10b5-1 plan is a common practice to avoid accusations of insider trading.

Comparison to Industry Standards

• Sales by directors under 10b5-1 plans are common across the industry, including companies like Medtronic and Abbott, which also have directors who use these plans for stock transactions.
• The volume of shares sold is relatively small compared to the total outstanding shares of Dexcom, and is not unusual for a director's planned sale.

Stakeholder Impact

• The sale is unlikely to have a significant impact on shareholders, as it is a small transaction by a single director under a pre-arranged plan.

Key Dates

Keywords

Dexcom, Director, Share Sale, 10b5-1 Plan, Stock Transaction, Insider Trading